Showing results (11-20 of 70) with videos related to
Sort By:
Pageof 7
Drug and Alcohol Dependence Reports|March 30, 2023
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorderChristian Heidbreder, Paul J Fudala, Mark K GreenwaldCurrent Topics in Behavioral Neurosciences|May 11, 2022
Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use DisordersAmy Hauck Newman, Zheng-Xiong Xi, Christian HeidbrederDrug and Alcohol Dependence Reports|February 27, 2023
The introduction of a novel formulation of buprenorphine into organized health systemsWilliam Mullen, Michaela Hedberg, Brian Gadbois, et al.Neuroscience Applied|July 14, 2025
A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disordersClare M Murray, J Craig Fox, Christian Heidbreder, et al.Journal of Neuroscience Methods|June 1, 2005
Non-invasive in vivo infrared laser spectroscopy to analyse endogenous oxy-haemoglobin, deoxy-haemoglobin, and blood volume in the rat CNSFrancesco Crespi, Andrea Bandera, Maurizio Donini, et al.Clinical Pharmacokinetics|January 22, 2015
Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy VolunteersAzmi F Nasser, Christian Heidbreder, Yongzhen Liu, et al.Journal of Neuroscience Methods|December 14, 2004
In vivo voltammetry: from wire to wireless measurementsFrancesco Crespi, Davide Dalessandro, Valerio Annovazzi-Lodi, et al.Neurochemistry International|September 10, 2009
The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitizationDavide Quarta, Enzo Valerio, Daniel M Hutcheson, et al.Journal of Pharmaceutical and Biomedical Analysis|January 6, 2016
Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometryYongzhen Liu, Xiaohua Li, Allan Xu, et al.Schizophrenia Research|April 13, 2016
Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 studyJohn J Isitt, Vijay R Nadipelli, Alex Kouassi, et al.Pageof 7